封面
市場調查報告書
商品編碼
2178184

生殖器皰疹治療市場:全球市場預測,2026-2032年

Genital Herpes Treatment Drug Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,生殖器皰疹治療市場規模將成長至 37.1 億美元,複合年成長率為 5.43%。

主要市場統計數據
基準年 2025 25.6億美元
預計年份:2026年 27億美元
預測年份 2032 37.1億美元
複合年成長率 (%) 5.43%

生殖器皰疹治療市場概覽

生殖器皰疹主要由2型單純皰疹病毒(HSV-2)引起,但第1型單純皰疹病毒(HSV-1)也可能導致生殖器感染。治療重點在於縮短症狀持續時間、減輕皮損嚴重程度、減少病毒脫落和降低復發頻率,而非根除潛伏感染。常用的抗病毒藥物包括阿昔洛韋、伐昔洛韋和泛昔洛韋,可用於治療初次發作、控制復發或進行病毒抑制治療。臨床決策需綜合考慮復發模式、免疫狀態、懷孕狀況、耐受性、用藥依從性以及當地的治療指南。

治療方式正朝著早期診斷和以患者為中心的照護方向轉變。

隨著人們對無症狀感染的認知不斷提高,性健康篩檢的討論日益廣泛,以及對諮詢和伴侶保護的重視程度不斷加深,治療方法正在轉變。由於許多感染仍未被診斷或臨床識別,因此將檢測、症狀評估、治療啟動、復發預防和預防性諮詢等環節銜接起來的診療路徑變得癒發重要。以患者為中心的照護也變得至關重要,包括提供私密的治療途徑、簡化的給藥方式、遠端醫療諮詢以及關於用藥依從性和資訊揭露的清晰指導。

人工智慧可以提升診斷、用藥依從性和調查工作流程。

人工智慧可以透過改善臨床試驗參與者招募、識別症狀記錄中的模式以及幫助醫療系統優先安排復發或併發症患者的隨訪,為該領域提供支援。自然語言處理工具可用於病患教育和用藥依從性提醒,而分析模型可以幫助研究人員評估復發模式和治療反應。這些應用需要嚴格的檢驗,因為生殖器病變可能由多種原因引起,診斷資料可能不完整,而且對於高度敏感的性健康資訊而言,隱私保護至關重要。

區域性洞察:醫療資源取得方面的差異會影響治療途徑。

在北美,雖然抗病毒藥物的取得途徑普遍完善,且擁有廣泛的專家和檢測機構網路,但經濟負擔、保險覆蓋範圍以及社會歧視仍然會影響就醫。在歐洲,許多國家受益於協調的公共衛生體系,但診斷實踐和保險報銷因國家而異。在亞太地區,醫療基礎設施差異顯著,都市區地區的醫療服務通常優於農村地區,且檢測和諮詢服務方面存在巨大差距。在拉丁美洲,性健康服務和診斷能力存在差異。在中東,文化因素和隱私保護對於獲得醫療服務至關重要。在非洲,仍需加強檢測能力,改善臨床培訓,並將生殖器皰疹的管理納入更廣泛的性與生殖健康服務系統。

團體分析:政策與貿易的協調一致影響護理的一致性

在東協市場,由於大都會圈居民在監管體系、醫療資金和醫療服務取得方面存在差異,區域和諧與人力資源發展至關重要。金磚國家成員國擁有龐大且多元化的患者群體,其診斷基礎設施、國內生產能力和公共部門服務模式各不相同。歐盟成員國受益於通用的公共衛生優先事項,同時維持各自的國家報銷機制和處方框架。七國集團(G7)的醫療衛生體系通常擁有強大的研究和臨床基礎設施,但與費用、污名化和醫療服務不足人口相關的差異仍然存在。在海灣合作理事會(GCC)國家,往往既有資源相對豐富的都市區醫療服務,又需要保密且具有文化敏感性的性健康服務。北約成員國的醫療衛生體系各不相同,因此加入北約並不一定意味著在治療或臨床實踐方面享有統一的待遇。

各國概況:每個國家的醫療保健系統都有其獨特的治療重點。

澳洲和加拿大優先在其地域分散的人口中推行基於指南的醫療保健。巴西和墨西哥必須應對區域差異、經濟負擔以及獲得保密診斷等挑戰。中國和印度的都市區醫療保健服務存在顯著差異,並且持續需要可擴展的檢測、諮詢和治療途徑。日本和韓國擁有先進的醫療保健能力,並有機會提高公眾意識和減少歧視。法國、德國、義大利和西班牙均處於成熟的歐洲醫療保健體系內,但在保險報銷、處方規範和服務組織方面存在差異。英國受益於完善的性健康服務,而美國提供多種治療選擇,但在保險覆蓋範圍、經濟負擔和醫療服務的連續性方面存在顯著差異。俄羅斯的醫療保健格局受到區域差異、醫療保健服務可近性以及對可靠的性健康教育和診斷服務的需求的影響。

給領導者的建議:加強獲取途徑、證據和負責任的創新

產業領導者應優先考慮實證抗病毒藥物的研發、便捷的給藥方式以及有助於提高用藥依從性的製劑,同時避免過度誇大臨床獲益。與性健康服務提供者的合作可以加強診斷、諮詢和轉診途徑,尤其是在服務不足的社區。患者資料應使用清晰易懂且不帶歧視的語言解釋傳播途徑、復發、妊娠注意事項和治療限制。應用人工智慧的機構應建立臨床有效性檢驗、網路安全、可解釋性、偏差監測以及對敏感資料的嚴格處理機制。打入市場策略應考慮國家醫保報銷規定、公共衛生採購、學名藥競爭以及資源豐富和資源匱乏環境下的不同需求。

調查方法:基於證據的治療動態評估

本執行摘要回顧了已建立的臨床發現、公共衛生指南、監管原則、同行評審研究以及已記錄的醫療保健系統特徵。分析區分了HSV-1和HSV-2的考慮因素,區分了癲癇治療和抑制療法的使用,並透過診斷、處方、經濟負擔、藥物依從性和預防性諮詢評估了醫療服務的可及性。區域、群體和國家層級的觀察結果以定性比較而非數值市場測量的方式呈現。本摘要未使用任何市場規模估算、市場佔有率、預測或公司特定聲明。

結論:有效的照護不僅需要治療,還需要預防支持。

儘管目前已有成熟的抗病毒療法可用於治療生殖器皰疹,但其臨床療效取決於及時診斷、選擇合適的治療方案、患者堅持服藥、有效控制復發以及提供充分的諮詢。地區和國家在社會歧視、醫療保健體系、保險報銷和診斷途徑等方面的差異,仍會影響治療效果。那些能夠將成熟的創新技術與保密、公平且以病人為中心的服務結合的醫療機構,將更有能力在維護科學、倫理和隱私標準的前提下,提高醫療品質。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章 生殖器皰疹治療市場:依藥物類型分類

  • 阿昔洛韋
  • 泛昔洛韋
  • 伐昔洛韋

第8章 生殖器皰疹治療市場:依劑型分類

  • 注射藥物
  • 口服錠劑
  • 外用乳膏

第9章:生殖器皰疹治療市場:依適應症分類

  • 首次發作
  • 復發
  • 抑制療法

第10章 生殖器皰疹治療市場:依通路分類

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
  • 零售藥房

第11章 生殖器皰疹治療市場:依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第12章 生殖器皰疹治療市場:按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 生殖器皰疹治療市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 生殖器皰疹治療市場:依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第16章:公司簡介

  • Apotex Inc.
  • Aurobindo Pharma Ltd
  • Bausch Health Companies Inc
  • Cipla Ltd
  • Dr. Reddy's Laboratories Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Rational Vaccines Inc.
  • Sandoz International GmbH
  • Shanghai Pharma Group
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc

第17章 主要專家

Product Code: MRR-4772A753B0B4

The Genital Herpes Treatment Drug Market is projected to grow by USD 3.71 billion at a CAGR of 5.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.56 billion
Estimated Year [2026] USD 2.70 billion
Forecast Year [2032] USD 3.71 billion
CAGR (%) 5.43%

Genital Herpes Treatment Drug Market: Executive Overview

Genital herpes is primarily caused by herpes simplex virus type 2 (HSV-2), although HSV-1 also contributes to genital infections. Treatment focuses on reducing symptom duration, lesion severity, viral shedding, and recurrence frequency; it does not eradicate latent infection. Established antiviral options include acyclovir, valacyclovir, and famciclovir, prescribed for first episodes, episodic recurrence management, or suppressive therapy. Clinical decisions depend on recurrence pattern, immune status, pregnancy considerations, tolerability, adherence, and local treatment guidance.

Treatment Is Shifting Toward Earlier Diagnosis and Patient-Centered Care

The treatment landscape is being reshaped by improved awareness of asymptomatic transmission, broader sexual-health screening discussions, and greater emphasis on counseling and partner protection. Because many infections remain undiagnosed or clinically unrecognized, care pathways increasingly connect testing, symptom assessment, treatment initiation, recurrence planning, and prevention counseling. Patient-centered delivery is also becoming more important, including discreet access, simplified dosing, telehealth-supported consultations, and clear guidance on medication adherence and disclosure.

Artificial Intelligence Strengthens Diagnosis, Adherence, and Research Workflows

Artificial intelligence can support this field by improving clinical-trial recruitment, identifying patterns in symptom documentation, and helping healthcare systems prioritize follow-up for patients with recurrent or complicated disease. Natural-language tools may assist with patient education and adherence reminders, while analytical models can help researchers evaluate recurrence patterns and treatment response. These applications require rigorous validation because genital lesions have multiple possible causes, diagnostic data may be incomplete, and privacy protections are essential for highly sensitive sexual-health information.

Regional Insights: Uneven Access Shapes Treatment Pathways

North America generally combines established antiviral availability with broad specialist and laboratory capacity, while affordability, insurance coverage, and stigma can still affect access. Europe benefits from coordinated public-health systems in many countries, although diagnostic practices and reimbursement differ across national settings. Asia-Pacific contains highly diverse healthcare infrastructures, with urban access often stronger than rural access and substantial variation in testing and counseling services. Latin America faces uneven availability of sexual-health services and diagnostic capacity. In the Middle East, cultural sensitivity and confidentiality are central to care access. Africa continues to require stronger laboratory capacity, clinical training, and integration of genital herpes management into broader sexual and reproductive health services.

Group Insights: Policy and Trade Alignment Affect Care Consistency

ASEAN markets show varied regulatory systems, healthcare financing, and access between metropolitan and rural populations, making regional harmonization and workforce training valuable. BRICS members span large and diverse patient populations with differing diagnostic infrastructure, domestic manufacturing capabilities, and public-sector access models. European Union countries benefit from shared public-health priorities while retaining national reimbursement and prescribing frameworks. G7 systems generally have stronger research and clinical infrastructure, but disparities related to cost, stigma, and underserved populations remain. GCC countries often combine comparatively well-resourced urban healthcare with a need for confidential, culturally responsive sexual-health services. NATO members represent diverse health systems, so alliance membership does not imply uniform treatment access or clinical practice.

Country Insights: National Systems Create Distinct Treatment Priorities

Australia and Canada emphasize guideline-based care across geographically dispersed populations. Brazil and Mexico must address regional disparities, affordability, and access to confidential diagnosis. China and India face substantial differences between urban and rural services and continue to require scalable testing, counseling, and treatment pathways. Japan and South Korea combine advanced healthcare capacity with opportunities to improve awareness and reduce stigma. France, Germany, Italy, and Spain operate within mature European systems, but reimbursement, prescribing norms, and service organization differ. The United Kingdom benefits from established sexual-health services, while the United States combines broad therapeutic availability with pronounced differences in insurance coverage, affordability, and continuity of care. Russia's care environment is shaped by regional variation, healthcare access, and the need for reliable sexual-health education and diagnostic services.

Recommendations for Leaders: Improve Access, Evidence, and Responsible Innovation

Industry leaders should prioritize evidence-based antiviral development, convenient regimens, and formulations that support adherence without overstating clinical benefits. Partnerships with sexual-health providers can strengthen diagnosis, counseling, and referral pathways, particularly for underserved communities. Patient materials should use clear, stigma-sensitive language and explain transmission, recurrence, pregnancy considerations, and the limits of treatment. Organizations deploying artificial intelligence should establish clinical validation, cybersecurity, explainability, bias monitoring, and strict handling of sensitive data. Market access strategies should account for national reimbursement rules, public-health procurement, generic competition, and the differing needs of high-resource and resource-constrained settings.

Research Methodology: Evidence-Led Assessment of Treatment Dynamics

This executive summary applies a structured review of established clinical knowledge, public-health guidance, regulatory principles, peer-reviewed research, and documented healthcare-system characteristics. The analysis distinguishes HSV-1 and HSV-2 considerations, separates episodic from suppressive treatment use, and evaluates access through diagnosis, prescribing, affordability, adherence, and prevention counseling. Regional, group, and country observations are presented as qualitative comparisons rather than numerical market measurements. No market estimates, market shares, forecasts, or company-specific claims are used.

Conclusion: Effective Care Depends on Treatment Plus Prevention Support

Genital herpes treatment is supported by established antiviral therapy, but clinical value depends on timely diagnosis, appropriate regimen selection, adherence, recurrence management, and informed counseling. Regional and national differences in stigma, healthcare capacity, reimbursement, and diagnostic access continue to shape outcomes. Leaders that combine validated innovation with confidential, equitable, and patient-centered services will be better positioned to improve care quality while maintaining scientific, ethical, and privacy standards.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Genital Herpes Treatment Drug Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Acyclovir
  • 7.3. Famciclovir
  • 7.4. Valacyclovir

8. Genital Herpes Treatment Drug Market, by Formulation

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral Tablet
  • 8.4. Topical Cream

9. Genital Herpes Treatment Drug Market, by Indication

  • 9.1. Introduction
  • 9.2. Initial Outbreak
  • 9.3. Recurrent Outbreak
  • 9.4. Suppressive Therapy

10. Genital Herpes Treatment Drug Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
    • 10.2.1. Private Hospital
    • 10.2.2. Public Hospital
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Genital Herpes Treatment Drug Market, by Route Of Administration

  • 11.1. Introduction
  • 11.2. Oral
  • 11.3. Parenteral
  • 11.4. Topical

12. Genital Herpes Treatment Drug Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Genital Herpes Treatment Drug Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Genital Herpes Treatment Drug Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Apotex Inc.
  • 16.2. Aurobindo Pharma Ltd
  • 16.3. Bausch Health Companies Inc
  • 16.4. Cipla Ltd
  • 16.5. Dr. Reddy's Laboratories Ltd
  • 16.6. GlaxoSmithKline plc
  • 16.7. Lupin Limited
  • 16.8. Merck & Co., Inc.
  • 16.9. Novartis AG
  • 16.10. Rational Vaccines Inc.
  • 16.11. Sandoz International GmbH
  • 16.12. Shanghai Pharma Group
  • 16.13. Sun Pharmaceutical Industries Ltd
  • 16.14. Teva Pharmaceutical Industries Ltd
  • 16.15. Viatris Inc

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Genital Herpes Treatment Drug Market, Years Considered for the Study
  • FIGURE 2. Global Genital Herpes Treatment Drug Market, Research Design
  • FIGURE 3. Global Genital Herpes Treatment Drug Market, Research Framework
  • FIGURE 4. Global Genital Herpes Treatment Drug Market, Data Triangulation
  • FIGURE 5. Global Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Genital Herpes Treatment Drug Market Size, by Drug Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Genital Herpes Treatment Drug Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Genital Herpes Treatment Drug Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 9. Global Genital Herpes Treatment Drug Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Genital Herpes Treatment Drug Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 11. Global Genital Herpes Treatment Drug Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 13. Global Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 15. Global Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Genital Herpes Treatment Drug Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Genital Herpes Treatment Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Genital Herpes Treatment Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Genital Herpes Treatment Drug Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Genital Herpes Treatment Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Genital Herpes Treatment Drug Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Genital Herpes Treatment Drug Market Segmentation & Coverage
  • TABLE 2. Global Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 4. Global Acyclovir Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Acyclovir Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Acyclovir Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Famciclovir Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Famciclovir Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Famciclovir Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Valacyclovir Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Valacyclovir Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Valacyclovir Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 14. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Oral Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Oral Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Oral Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Topical Cream Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Topical Cream Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Topical Cream Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 24. Global Initial Outbreak Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Initial Outbreak Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Initial Outbreak Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Recurrent Outbreak Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Recurrent Outbreak Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Recurrent Outbreak Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Suppressive Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Suppressive Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Suppressive Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 34. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Private Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Private Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Private Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Public Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Public Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Public Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 50. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Topical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Topical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Topical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 62. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 63. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 64. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 67. North America Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. North America Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 69. North America Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 70. North America Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 71. North America Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 72. North America Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 73. North America Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 74. Latin America Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Latin America Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 76. Latin America Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 77. Latin America Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 78. Latin America Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 79. Latin America Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 80. Latin America Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 81. Europe Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Europe Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 83. Europe Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 84. Europe Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 85. Europe Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 86. Europe Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 87. Europe Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 88. Middle East Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Middle East Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 90. Middle East Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 91. Middle East Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 92. Middle East Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. Middle East Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 94. Middle East Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 95. Africa Genital Herpes Treatment Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Africa Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 97. Africa Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 98. Africa Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 99. Africa Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 100. Africa Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 101. Africa Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 102. Global Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. ASEAN Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. ASEAN Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 105. ASEAN Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 106. ASEAN Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 107. ASEAN Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 108. ASEAN Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 109. ASEAN Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 110. GCC Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 111. GCC Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 112. GCC Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 113. GCC Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 114. GCC Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. GCC Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 116. GCC Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 117. European Union Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 118. European Union Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 119. European Union Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 120. European Union Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 121. European Union Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 122. European Union Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 123. European Union Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 124. BRICS Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. BRICS Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 126. BRICS Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 127. BRICS Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 128. BRICS Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 129. BRICS Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 130. BRICS Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 131. G7 Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 132. G7 Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 133. G7 Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 134. G7 Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 135. G7 Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 136. G7 Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 137. G7 Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 138. NATO Genital Herpes Treatment Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 139. NATO Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 140. NATO Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 141. NATO Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 142. NATO Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. NATO Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 144. NATO Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 145. Global Genital Herpes Treatment Drug Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 146. United States Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 147. United States Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 148. United States Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 149. United States Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 150. United States Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 151. United States Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 152. United States Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. Canada Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 154. Canada Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 155. Canada Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 156. Canada Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 157. Canada Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. Canada Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 159. Canada Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 160. Mexico Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 161. Mexico Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 162. Mexico Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 163. Mexico Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 164. Mexico Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 165. Mexico Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 166. Mexico Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 167. Brazil Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 168. Brazil Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 169. Brazil Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 170. Brazil Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 171. Brazil Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 172. Brazil Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 173. Brazil Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 174. United Kingdom Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 175. United Kingdom Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 176. United Kingdom Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 177. United Kingdom Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 178. United Kingdom Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 179. United Kingdom Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 180. United Kingdom Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 181. Germany Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 182. Germany Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 183. Germany Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 184. Germany Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 185. Germany Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 186. Germany Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 187. Germany Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 188. France Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 189. France Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 190. France Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 191. France Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 192. France Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 193. France Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 194. France Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 195. Russia Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 196. Russia Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 197. Russia Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 198. Russia Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 199. Russia Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 200. Russia Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 201. Russia Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 202. Italy Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 203. Italy Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 204. Italy Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 205. Italy Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 206. Italy Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Italy Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 208. Italy Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 209. Spain Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 210. Spain Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 211. Spain Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 212. Spain Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 213. Spain Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 214. Spain Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 215. Spain Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 216. China Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 217. China Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 218. China Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 219. China Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 220. China Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 221. China Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 222. China Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 223. India Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 224. India Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 225. India Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 226. India Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 227. India Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 228. India Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 229. India Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 230. Japan Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 231. Japan Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 232. Japan Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 233. Japan Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 234. Japan Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 235. Japan Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 236. Japan Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 237. Australia Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 238. Australia Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 239. Australia Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 240. Australia Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 241. Australia Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 242. Australia Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 243. Australia Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. South Korea Genital Herpes Treatment Drug Market Size, 2017-2032 (USD Million)
  • TABLE 245. South Korea Genital Herpes Treatment Drug Market Size, by Drug Type, 2017-2032 (USD Million)
  • TABLE 246. South Korea Genital Herpes Treatment Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 247. South Korea Genital Herpes Treatment Drug Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 248. South Korea Genital Herpes Treatment Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 249. South Korea Genital Herpes Treatment Drug Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
  • TABLE 250. South Korea Genital Herpes Treatment Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 251. Global Genital Herpes Treatment Drug Market Share, by Key Player, 2025
  • TABLE 252. Global Genital Herpes Treatment Drug Market, Key Experts